Show simple item record

dc.contributor.authorMarshall, Rachel
dc.contributor.authorPopple, Amy
dc.contributor.authorKordbacheh, Tiana
dc.contributor.authorHoneychurch, Jamie
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorIllidge, Timothy M
dc.date.accessioned2017-01-27T18:22:59Z
dc.date.available2017-01-27T18:22:59Z
dc.date.issued2017-01-04
dc.identifier.citationImmune checkpoint inhibitors in lung cancer - an unheralded opportunity? 2017, Clin Oncolen
dc.identifier.issn1433-2981
dc.identifier.pmid28063623
dc.identifier.doi10.1016/j.clon.2016.12.003
dc.identifier.urihttp://hdl.handle.net/10541/620096
dc.descriptionLymphoma Research Teamen
dc.description.abstractLung cancer remains the leading cause of cancer-related death worldwide, with non-small cell lung cancer accounting for 85% of the disease. Over 70% of patients present with locally advanced, non-resectable or metastatic disease and despite improvements in chemoradiotherapy regimens and the development of molecularly targeted agents, 5 year survival rates remain poor, with acquired resistance to novel targeted therapies becoming a growing concern. Currently there remains an unmet need in effectively treating and inducing durable responses in advanced disease. Targeting the immune system has, however, recently given hope of improving therapeutic outcomes for these patients. The notion that the immune system is capable of recognising and eliminating cancer cells is now a widely accepted phenomenon and growing evidence suggests lung cancer is an attractive target for such intervention. Recent success targeting the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis of immune checkpoint inhibition suggests a major immunotherapeutic advance in treating lung cancer and unheralded opportunity for such approaches to further improve outcome for patients. Currently there is considerable interest in combining anti-PD-1 or PD-L1 monoclonal antibodies with established standard of care therapies such as radiotherapy. Radiotherapy is known to be immunostimulatory and efforts are underway to combine and augment the efficacy of the immune checkpoint inhibitors further. This review outlines the interaction between lung cancer and the immune system, summarises current evidence supporting the use of monoclonal antibodies targeting the PD-1 axis in lung cancer and explores the potential of combining radiotherapy with immunotherapy to augment anti-tumour immune responses.
dc.language.isoenen
dc.rightsArchived with thanks to Clinical oncology (Royal College of Radiologists (Great Britain))en
dc.titleImmune checkpoint inhibitors in lung cancer - an unheralded opportunity?en
dc.typeArticleen
dc.contributor.departmentInstitute of Cancer Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UKen
dc.identifier.journalClinical Oncologyen
html.description.abstractLung cancer remains the leading cause of cancer-related death worldwide, with non-small cell lung cancer accounting for 85% of the disease. Over 70% of patients present with locally advanced, non-resectable or metastatic disease and despite improvements in chemoradiotherapy regimens and the development of molecularly targeted agents, 5 year survival rates remain poor, with acquired resistance to novel targeted therapies becoming a growing concern. Currently there remains an unmet need in effectively treating and inducing durable responses in advanced disease. Targeting the immune system has, however, recently given hope of improving therapeutic outcomes for these patients. The notion that the immune system is capable of recognising and eliminating cancer cells is now a widely accepted phenomenon and growing evidence suggests lung cancer is an attractive target for such intervention. Recent success targeting the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis of immune checkpoint inhibition suggests a major immunotherapeutic advance in treating lung cancer and unheralded opportunity for such approaches to further improve outcome for patients. Currently there is considerable interest in combining anti-PD-1 or PD-L1 monoclonal antibodies with established standard of care therapies such as radiotherapy. Radiotherapy is known to be immunostimulatory and efforts are underway to combine and augment the efficacy of the immune checkpoint inhibitors further. This review outlines the interaction between lung cancer and the immune system, summarises current evidence supporting the use of monoclonal antibodies targeting the PD-1 axis in lung cancer and explores the potential of combining radiotherapy with immunotherapy to augment anti-tumour immune responses.


Files in this item

This item appears in the following Collection(s)

Show simple item record